LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 935

Search options

  1. Article ; Online: SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape.

    Focosi, Daniele / Maggi, Fabrizio

    International journal of molecular sciences

    2023  Volume 24, Issue 3

    Abstract: In this Special Issue, many original contributions concerning serological methods for SARS-CoV-2 were collected, some of them with implications about therapeutics [ ... ]. ...

    Abstract In this Special Issue, many original contributions concerning serological methods for SARS-CoV-2 were collected, some of them with implications about therapeutics [...].
    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19 ; Antibodies ; Antibodies, Viral
    Chemical Substances Antibodies ; Antibodies, Viral
    Language English
    Publishing date 2023-01-27
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24032488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses.

    Focosi, Daniele / Maggi, Fabrizio

    Viruses

    2023  Volume 15, Issue 5

    Abstract: RNA viruses have developed notable strategies to evolve and escape host immunity [ ... ]. ...

    Abstract RNA viruses have developed notable strategies to evolve and escape host immunity [...].
    MeSH term(s) Humans ; SARS-CoV-2/genetics ; COVID-19
    Language English
    Publishing date 2023-04-26
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15051063
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules.

    Focosi, Daniele / Maggi, Fabrizio

    Viruses

    2023  Volume 15, Issue 3

    Abstract: SARS-CoV-2 genomic sequencing has peaked to unprecedented compared to other viruses [ ... ]. ...

    Abstract SARS-CoV-2 genomic sequencing has peaked to unprecedented compared to other viruses [...].
    MeSH term(s) Humans ; SARS-CoV-2/genetics ; COVID-19/genetics ; Big Data ; Viruses/genetics ; Genome, Viral
    Language English
    Publishing date 2023-03-09
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15030715
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy.

    Focosi, Daniele / Maggi, Fabrizio

    Human vaccines & immunotherapeutics

    2023  Volume 19, Issue 2, Page(s) 2260040

    Abstract: Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory ... ...

    Abstract Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory pathogen, respiratory delivery is preferable to maximize the amount of antibody that reaches the entry door in order to prevent sustained viral multiplication. In this narrative review, we review the different types of inhalation device and summarize evidence from animal models and early clinical trials supporting the respiratory delivery (for either prophylactic or therapeutic purposes) of convalescent plasma or monoclonal antibodies (either full antibodies, single-chain variable fragments, or camelid-derived monoclonal heavy-chain only antibodies). Preliminary evidences from animal models suggest similar safety and noninferior efficacy, but efficacy evaluation from clinical trials is still limited.
    MeSH term(s) Animals ; Humans ; SARS-CoV-2 ; COVID-19/prevention & control ; Pandemics/prevention & control ; Antibodies, Viral ; COVID-19 Serotherapy ; Immunization, Passive ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing
    Chemical Substances Antibodies, Viral ; Antibodies, Monoclonal ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.1080/21645515.2023.2260040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6967: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.

    Focosi, Daniele / Casadevall, Arturo / Franchini, Massimo / Maggi, Fabrizio

    Viruses

    2024  Volume 16, Issue 2

    Abstract: Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was the most successful in having the longest temporal window of clinical use, showing a high degree of resiliency to SARS-CoV-2 evolution interrupted only by the ... ...

    Abstract Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was the most successful in having the longest temporal window of clinical use, showing a high degree of resiliency to SARS-CoV-2 evolution interrupted only by the appearance of the BA.2.86* variant of interest (VOI). This success undoubtedly reflects rational selection to target a highly conserved epitope in coronavirus Spike proteins. We review here the efficacy of sotrovimab against different SARS-CoV-2 variants in outpatients and inpatients, discussing both randomized controlled trials and real-world evidence. Although it could not be anticipated at the time of its development and introduction, sotrovimab's use in immunocompromised individuals who harbor large populations of variant viruses created the conditions for its eventual demise, as antibody selection and viral evolution led to its eventual withdrawal due to inefficacy against later variant lineages. Despite this, based on observational and real-world data, some authorities have continued to promote the use of sotrovimab, but the lack of binding to newer variants strongly argues for the futility of continued use. The story of sotrovimab highlights the power of modern biomedical science to generate novel therapeutics while also providing a cautionary tale for the need to devise strategies to minimize the emergence of resistance to antibody-based therapeutics.
    MeSH term(s) Humans ; SARS-CoV-2/genetics ; COVID-19 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/therapeutic use
    Chemical Substances sotrovimab (1MTK0BPN8V) ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2024-01-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v16020217
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Online dashboards for SARS-CoV-2 wastewater-based epidemiology.

    Focosi, Daniele / Spezia, Pietro Giorgio / Maggi, Fabrizio

    Future microbiology

    2024  

    Abstract: Aim: ...

    Abstract Aim:
    Language English
    Publishing date 2024-05-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 2254620-0
    ISSN 1746-0921 ; 1746-0913
    ISSN (online) 1746-0921
    ISSN 1746-0913
    DOI 10.2217/fmb-2024-0033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2.

    Focosi, Daniele / Franchini, Massimo / Casadevall, Arturo / Maggi, Fabrizio

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2024  

    Abstract: Background: Anti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.: Objectives: We ...

    Abstract Background: Anti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.
    Objectives: We review here the current pipeline of anti-spike mAb's, discussing in detail the most promising candidates.
    Sources: We scanned PubMed, ClinicalTrials.gov and manufacturers' press releases for clinical studies on anti-spike monoclonal antibodies.
    Content: We present state-of-art data clinical progress for AstraZeneca's AZD3152, Invivyd's VYD222, Regeneron's REGN-17092 and Aerium Therapeutics' AER-800.
    Implications: The anti-spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions.
    Language English
    Publishing date 2024-04-24
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2024.04.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 284: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: COVID-19 therapeutics.

    Focosi, Daniele / Franchini, Massimo / Maggi, Fabrizio / Shoham, Shmuel

    Clinical microbiology reviews

    2024  , Page(s) e0011923

    Abstract: SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains ... ...

    Abstract SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.
    Language English
    Publishing date 2024-05-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 645015-5
    ISSN 1098-6618 ; 0893-8512
    ISSN (online) 1098-6618
    ISSN 0893-8512
    DOI 10.1128/cmr.00119-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2409: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline.

    Focosi, Daniele / Maggi, Fabrizio

    Viruses

    2022  Volume 14, Issue 11

    Abstract: The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated ... ...

    Abstract The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.
    MeSH term(s) Animals ; Humans ; COVID-19 Vaccines ; Viral Envelope Proteins/metabolism ; Antibodies, Viral/metabolism ; COVID-19/prevention & control ; SARS-CoV-2/genetics ; Vaccines ; Antibodies, Neutralizing/metabolism ; Spike Glycoprotein, Coronavirus/genetics
    Chemical Substances COVID-19 Vaccines ; Viral Envelope Proteins ; Antibodies, Viral ; Vaccines ; Antibodies, Neutralizing ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2022-11-10
    Publishing country Switzerland
    Document type Review ; Journal Article
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14112488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Insecticidal Activity of Plant Secondary Metabolites.

    Benelli, Giovanni / Maggi, Filippo

    Plants (Basel, Switzerland)

    2022  Volume 11, Issue 20

    Abstract: Plant-insect interactions are one of the most fascinating fields of research attracting biologists, entomologists, botanists, as well as a wide range of multidisciplinary researchers [ ... ]. ...

    Abstract Plant-insect interactions are one of the most fascinating fields of research attracting biologists, entomologists, botanists, as well as a wide range of multidisciplinary researchers [...].
    Language English
    Publishing date 2022-10-21
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2704341-1
    ISSN 2223-7747
    ISSN 2223-7747
    DOI 10.3390/plants11202804
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top